Search Results - carl+atkinson

2 Results Sort By:
M1/Mdivi1 as a novel treatment to reduce immunogenicity in organ transplantation
Technology: Addition of M1 and Mdivi1 drugs in organ preservation solutions can reduce the immunogenicity of the donor organ’s microvascular endothelial cells (ECs), thereby promoting allograft immune tolerance. Inventors at MUSC have found that the use of M1 (a mitochondrial fusion promoter) and Mdivi1 (a mitochondrial fission inhibitor) as a...
Published: 3/19/2018   |   Inventor(s): Satish Nadig, Carl Atkinson, Danh Tran
Keywords(s):  
Category(s): Therapeutic
Targeted Rapamycin Micelle (TRaM) as a Therapeutic and for Solid Organ Transplant
Technology: TRaMs are a novel therapeutic tool for immunosuppression during solid organ transplantation that encompasses a pH sensitive, self-assembling nanocarrier with encapsulated rapamycin and a targeting moiety for endothelial cells. TRaMs internalize more rapidly than non-targeted RaMs, suppress biomarkers of EC inflammation and reduce MHC expression...
Published: 4/4/2014   |   Inventor(s): Ann-Marie Broome, Suraj Dixit, Satish Nadig, Carl Atkinson
Keywords(s):  
Category(s): Therapeutic
© 2021. All Rights Reserved. Powered by Inteum